26 results about "CD90" patented technology

The present invention relates to CD73 + CD44 + , CD90 + A method for generating a population of mesenchymal stromal cells (MSCs) is provided. + CD44 + , CD90 + MSCs are used in methods to generate terminally differentiated osteogenic, adipogenic, and chondrogenic cells from pluripotent stem cells (PSCs), which involve the use of a single agent, a WNT signaling pathway activator (e.g., a GSK3β inhibitor), in adherent cultures of PSCs.

The present invention provides a combination comprising a) an antigen binding domain specific for CD90, and b) an antigen binding domain specific for CD326, for use in treatment of human cancer comprising cancerous cells that co-express CD90 and CD326. In one embodiment of the invention the combination comprises a) an immune cell comprising a CAR comprising an antigen binding domain specific for a tag of a first and a second polypeptide, b) said tagged first polypeptide that has an antigen binding domain specific for CD90, and c) said tagged second polypeptide that has an antigen binding domain specific for CD326, wherein the tag of the first polypeptide and the tag of the second polypeptide are identical. In a further embodiment the concentrations used for said first and that second polypeptide are below the activation threshold of said CAR, respectively, but the sum of both concentrations is above the activation threshold of said CAR.

This invention provides a cell population comprising mesenchymal cells capable of forming a cell sheet that can be spontaneously detached from a substrate. In such cell population comprising mesenchymal cells, the proportion of cells positive for CD324 is 70% or more and the proportion of mesenchymal cells positive for CD90 is 90% or more.

To provide safe and high-performance stem cells appropriate for clinical application, and a method for producing the stem cells.SOLUTION: Provided are a stem cell population derived from human deciduous tooth dental pulp, wherein 90% or more of the stem cell population is characterized by being CD117-negative, CD73-positive, CD90-positive, and CD105-positive, and a method for producing a stem cell population derived from human deciduous tooth dental pulp, the method comprising a step of culturing cells isolated from human deciduous tooth dental pulp in a medium that does not contain FBS (fetal bovine serum) in the presence of human platelet lysate (hPL).SELECTED DRAWING: None

This invention relates to the field of cell detection technology, specifically to a reagent tube for detecting mesenchymal stem cell phenotypes. The tube includes a reagent tube body and pre-encapsulated fluorescent antibody lyophilized microspheres. The lyophilized microspheres are formed by lyophilization of a mixture of lyophilization protection solution and fluorescently labeled antibody. The fluorescently labeled antibody is a combination of antibodies targeting positive markers of mesenchymal stem cell phenotypes CD73, CD90, and CD105, or a combination of antibodies targeting negative markers CD45, CD34, CD11b, CD19, and HLA-DR. This invention offers high efficiency and convenience: by pre-encapsulating the fluorescent antibody lyophilized microspheres, the traditional three-step process of "antibody preparation-sample addition-mixing" is simplified to direct addition of cell suspension. The single-sample detection time is reduced from 120 minutes to 30 minutes, the number of pipetting operations is reduced by 80%, and human error is significantly reduced.

Disclosed are a specific marker combination of mesenchymal stem cell-derived small extracellular vesicles and the use thereof. The characteristic marker combination comprises aminopeptidase N (CD13), integrin β-1 (CD29), membrane glycoprotein THY-1 (CD90), and markers CD9, CD63 and CD81. By using the characteristic marker combination of mesenchymal stem cell-derived small extracellular vesicles for nano-flow cytometry analysis at the single-vesicle level, mesenchymal stem cell-derived small extracellular vesicles can be identified. On the basis of the provided characteristic marker combination, specific modification and engineering on the basis of small extracellular vesicle membrane proteins can further be realized.

The invention provides an application of a composition, a culture medium additive or a culture medium in amplifying hematopoietic stem cells or preparing products for amplifying the hematopoietic stem cells. On the first aspect, the invention provides application of the composition, the culture medium additive or the culture medium to hematopoietic stem cell amplification or hematopoietic stem cell amplification product preparation. The composition comprises quininostat and resveratrol. The culture medium additive comprises a composition; the culture medium comprises a basic culture medium and an additive, wherein the additive comprises the composition. By screening the combination of a specific HDAC inhibitor and other various different small molecule compounds, the proportion of CD34 +, CD34 + CD90 + and CD34 + CD90 + EPCR + cells of HSC after in-vitro amplification can be obviously improved at a lower working concentration, namely, the proportion of hematopoietic stem cells and long-acting hematopoietic stem cells can be improved.

This application provides the use of a composition, culture medium additive, or culture medium in expanding hematopoietic stem cells or preparing products containing expanded hematopoietic stem cells. A first aspect of this application discloses the use of a composition, culture medium additive, or culture medium in expanding hematopoietic stem cells or preparing products containing expanded hematopoietic stem cells. The composition includes quinsinostat and resveratrol; the culture medium additive includes the composition; the culture medium includes a basal medium and an additive, the additive including the composition. By screening specific HDAC inhibitors and combinations of various other small molecule compounds, the CD34 concentration of HSCs after in vitro expansion can be significantly increased at lower working concentrations. + CD34 + CD90 + and CD34 + CD90 + EPCR + The proportion of cells, that is, the proportion of hematopoietic stem cells and long-acting hematopoietic stem cells, can be increased.

The application belongs to the field of cell culture. The application provides a culture medium of rat amniotic membrane mesenchymal stem cells and a culture method of rat amniotic membrane mesenchymal stem cells. The culture medium is a complete culture medium, and the culture method is as follows: the rat amnion is cut into tissue blocks smaller than 2mm 2 , is uniformly laid in a culture dish with a spacing of 0.3-0.8cm, complete culture medium is slowly added after the tissue blocks are adhered, the culture medium is supplemented after 12h-36h, the primary medium replacement is performed after 48h-72h of culture, the impurity cells are removed, and the cells are subcultured when the cell fusion degree reaches 80%-90%. The light microscope observation and identification result show that the rat amniotic membrane mesenchymal stem cells cultured by the application basically conform to the cell morphology of rat amniotic membrane mesenchymal stem cells, the CD90&DAPI immunofluorescence identification result shows that the cell purity is greater than or equal to 90%, the cells have the characteristics of stem cells, and the culture method is efficient in amplification.

Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.

The invention belongs to the technical field of biological medicines, and particularly relates to application of mesenchymal stem cells combined with mesalazine in preparation of an anti-IBD (infectious bursal disease) medicine. The mesenchymal stem cells are mesenchymal stem cells from human umbilical cord; the human umbilical cord mesenchymal stem cells highly express CD73, CD90 and CD65, and low express CD34, CD45 and HLA-DR (Human Leukocyte Antigen-DR). The research finds that the hUC-MSCs has a remarkable treatment effect on a chronic IBD mouse model when being singly used or combined with 5-ASA for treatment, the hUC-MSCs and drug combination can restore the intestinal microecological balance by adjusting the composition of intestinal flora so as to improve the symptoms of IBD, and the hUC-MSCs and the drug combination have a synergistic effect when being combined with 5-ASA for treatment. The invention provides a new thought and experimental basis for clinical treatment of IBD.

The present invention provides compositions and methods for promoting the engraftment of exogenous hematopoietic stem cell grafts and for maintaining the pluripotency and hematopoietic function of these cells after transplantation. [Solution] The present invention provides compositions and methods useful for the depletion of cells such as CD45+, CD135+, CD34+, CD90+, and / or CD110+ cells, and, in particular, for the treatment of various hematopoietic disorders, metabolic disorders, cancer, and autoimmune diseases. For example, antibodies, their antigen-binding fragments, ligands, and conjugates that can be applied to achieve the treatment of these conditions by depleting populations of D45+, CD135+, CD34+, CD90+, or CD110+ cells in a patient such as a human are described herein.

This invention relates to a ZIF-8-based composite nanoparticle with a core-shell structure. The core is a zeolite imidazole ester backbone ZIF-8 carrier, and the pores of the ZIF-8 core are loaded with a photothermal agent. Liposomes are coated on the outer surface of the core as a shell, and CD90 antibodies are coupled to the surface of the liposomes. The composite nanoparticle targets mesenchymal stem cells, thereby more effectively delivering zinc ions into mesenchymal stem cells (MSCs) to regulate MMP-10 (matrix metalloproteinase-10) expression. The composite nanoparticle can be used to prepare drugs or medical dressings for treating bone defects and / or promoting vascularized bone regeneration.

The present invention provides a method of producing a thymic construct suitable for implantation into a subject, the method comprising the steps of: (i) providing a decellularised scaffold; (ii) seeding the decellularised scaffold with thymic epithelial cells having mesenchymal properties; and (iii) culturing the seeded scaffold to produce the construct. The thymic epithelial cells are preferably CD49f + , also VIM + , TE-7 + , and / or CD90 + . The present invention further provides pharmaceutical compositions, uses and therapies using thymic epithelial cells having mesenchymal properties.

The invention provides methods for generating human CD34+, CD43+, and CD90+ hematopoietic progenitor cells from hematopoietic stem cells. The methods include the use of chemically-defined culture media. Isolated cell populations are also provided.

The invention provides methods for generating human CD34+, CD43+, and CD90+ hematopoietic progenitor cells from hematopoietic stem cells. The methods include the use of chemically-defined culture media. Isolated cell populations are also provided.

The invention discloses application of hAMSCs injected in different modes in preparation of drugs for improving pulmonary fibrosis EMT and apoptosis, and relates to the technical field of medicines. The hAMSCs provided by the invention are the third generation to the fifth generation of hAMSCs obtained by subculture, the hAMSCs highly express MSCs symbolic protein CD90, CD105, CD44 and CD73, and the hAMSCs lowly express CD11b, CD34, CD45 and CD19. The invention has proved that the expression of an epithelial marker E-cadherin can be increased by intratracheal or caudal vein injection of hAMSCs, and the expression of an interstitial marker vimentin is inhibited at the same time, so that the occurrence and development of IPF are prevented. A new thought is provided for preventing and preparing the IPF medicine.

The application discloses application of TACSTD2 protein in preparation of products for detecting and identifying human amniotic epithelial cells, and belongs to the technical field of biological medicines. The application proposes a protein marker for detecting and identifying human amniotic epithelial stem cells, which comprises TACSTD2 protein, or TACSTD2 protein combined with one or more selected from CD29, CD166, CD73, CD90, CD105, CD324, CD326, SSEA4, Nestin and Vimentin. The application further proposes application of a reagent for detecting TACSTD2 protein expression in preparation of products for detecting and identifying human amniotic epithelial cells, which is specifically highly expressed in human amniotic epithelial stem cells and can be used alone or in combination with other cells for detecting and identifying human amniotic epithelial cells.

The invention discloses a mesenchymal stem cell culture medium containing traditional Chinese medicine components and a preparation method and application thereof. The mesenchymal stem cell culture medium is a culture system composed of a basic culture medium and additives. DMEM / F12 is used as a basic culture medium, an additive solution comprises fetal calf serum, an American ginseng extract and a ganoderma spore extract, and the cell anti-inflammatory capacity, the repair promoting capacity and the angiogenesis promoting capacity are improved. The mesenchymal stem cell culture medium containing the traditional Chinese medicine components can be used for culturing mesenchymal stem cells, and after cells are inoculated for 24 hours, the original culture medium is abandoned, and the culture medium is replaced. By using the culture medium and the use method, the positive rate of the obtained mesenchymal stem cells CD73, CD90 and CD105 is greater than 95%, the positive rate of the obtained mesenchymal stem cells CD44, CD45, CD19, CD34, CD14 and HLA-DR is less than 2%, and the amplification efficiency is improved. Higher anti-inflammatory, repair-promoting and angiogenesis-promoting capacities are realized.

The invention relates to the technical field of biological medicine, in particular to a CD90-targeted nano-drug delivery system and application of the CD90-targeted nano-drug delivery system in preparation of a drug for treating alopecia senescens. Efficient loading and stable release of an anti-aging drug dihydroartemisinin (DHA) are realized through the dendritic ordered porous structure; furthermore, the surfaces of the nano-particles are covalently modified by using a CD90-targeting aptamer A15518, so that the nano-particles are endowed with the targeting capability of selectively recognizing the senescent hair follicle stem cells and the microenvironment of the senescent hair follicle stem cells. The nano-drug delivery system provided by the invention can significantly improve the enrichment efficiency of the drug at the hair follicle part, enhance the regulation effect of the drug on the aging-related pathway, and promote the aging hair follicle to enter the growth period, so that the nano-drug delivery system can be used for preparing drugs or related preparations for treating aging alopecia.

The invention provides a method for separating and extracting amniotic mesenchymal stem cells from a placenta. The method comprises the following steps: S1, pretreating the placenta; s2, amniotic membrane tissue separation; s3, tissue crushing; s4, enzymolysis digestion: softening the fragments, and mixing the softened fragments with a compound enzyme solution according to a mass-volume ratio of 1: (8-12) to obtain an enzymolysis product; s5, centrifugal separation: performing gradient centrifugation on the enzymolysis product to obtain cell precipitate; s6, cell culture: inoculating cell precipitates obtained by centrifugation to a compound culture medium; and step S7, immune sorting: separating target cells by adopting CD90 antibody coated magnetic beads. According to the method disclosed by the invention, three defects of cell injury, insufficient purity and low yield are synchronously overcome through a softening liquid protection mechanism, multi-enzyme synergistic dissociation, gradient centrifugal layering and other core technologies; and standardized parameter control (such as thickness cutting and temperature gradient) ensures the process reproducibility, and provides high-activity and high-purity functional stem cells for clinical application.

The present application relates to stem cell technology, in particular to a pet stem cell induction medium, a preparation method and a culture method, the medium significantly improves the proliferation efficiency and multi-directional differentiation potential of adipose-derived stem cells by optimizing the ratio of specific growth factors. The preparation method comprises the steps of preparing a basic medium, adding growth factors and sterile filtering. Experimental verification shows that compared with the control group, the adipogenic differentiation efficiency of ADSCs cultured in the medium is increased by 40%, the osteogenic differentiation ALP activity is increased by 65%, and the positive rates of surface markers CD29, CD44 and CD90 are all greater than or equal to 95%. The present application solves the problems of animal source pathogen contamination risk and low induction efficiency of traditional culture medium, and is suitable for pet medical treatment.

The present invention relates to a culture method for culturing a population of endothelial colony-forming cells (ECFC) derived from umbilical cord blood, the method comprising: (a) holding an umbilical cord blood sample obtained from a subject at a temperature of 4 DEG C to 15 DEG C for 24 hours to 72 hours; (b) isolating mononuclear cells from the blood sample; (c) inoculating the mononuclear cells on a culture substrate; (d) culturing the inoculated adherent monocytes in a culture medium for about 5 days to about 21 days to form colonies comprising cells; and (e) culturing the cells which express the CD31, the CD34, the CD105, the CD144, the CD146, the CD157 and the VEGFR2 (vascular endothelial growth factor receptor 2) but do not express the CD45, the CD14 and the CD90.

A method for producing an enriched population of human MSCs, comprising culturing isolated MSCs in xeno-free medium to at least 80% confluence, followed by treatment with a priming agent: erastin, sulfasalazine, or a combination thereof, to produce expanded MSCs positive for CD73, CD90, and CD105. A method is also provided for treating or preventing tissue damage or dysfunction, comprising the aforementioned method involving priming of human MSCs with a low dose of a priming agent. Further, a composition comprising primed MSCs and a cell culture medium system including the priming agent. Accordingly, the low-dose FINs offer a novel approach as a priming agent in large-scale stem cell expansion process. And the primed MSCs after low-dose FINs treatment could be applied to transplantation into oxidative and inflammatory microenvironments.

The present application provides a standard for quality evaluation or determination of a subject cell, comprising: a high-speed proliferative mesenchymal stem cell population characterized by positive or negative of at least one marker of LNGFR (CD271) and Thy-1 (CD90).